Last checked at 
(Alliance News) - ReNeuron Group PLC on Friday said "positive" progress is being made with its exosome technology platform, signing several collaboration agreements.
The Bridgend, Wales-based developer of cell-based therapeutics said it has signed a further commercial collaboration agreement with a "major" unnamed pharmaceutical company that will focus on the potential of its exosomes to deliver DNA cargoes for expression of therapeutic genes in the brain.
Shares in ReNeuron were up 13% at 122.75 pence in London on Friday.
ReNeuron said it also initiated an additional two collaborations with "leading academic institutions" in the UK and mainland Europe, which will focus on the delivery of central nervous system-targeting growth factors and small interfering RNA molecules to the brain.
In addition, the company said it is developing further exosome candidates derived from its panel of additional producer cell lines. "These exosome candidates have the potential to broaden the repertoire of tissues and indications that the company is able to target," it added.
"Our exosome platform is being deployed in collaboration with commercial third parties and it is pleasing to report that these collaborations are progressing to plan, with exciting data now emerging to demonstrate the delivery potential of this technology with a range of novel therapeutic agents, targeting the brain and other tissues. We look forward to reporting further progress across these collaborations in the months ahead," said Chief Executive Olav Hellebo.
By Zoe Wickens; zoewickens@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
